These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 15269150)
1. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150 [TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer. Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C Oncology; 2012; 82(4):234-41. PubMed ID: 22508321 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777 [TBL] [Abstract][Full Text] [Related]
4. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120 [TBL] [Abstract][Full Text] [Related]
5. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949 [TBL] [Abstract][Full Text] [Related]
6. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Risch HA; Puopolo M; Yu H Clin Cancer Res; 2006 Feb; 12(4):1208-14. PubMed ID: 16489075 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815 [TBL] [Abstract][Full Text] [Related]
8. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948 [TBL] [Abstract][Full Text] [Related]
9. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443 [TBL] [Abstract][Full Text] [Related]
11. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Shigemasa K; Gu L; O'Brien TJ; Ohama K Clin Cancer Res; 2003 May; 9(5):1756-63. PubMed ID: 12738731 [TBL] [Abstract][Full Text] [Related]
12. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413 [TBL] [Abstract][Full Text] [Related]
13. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549 [TBL] [Abstract][Full Text] [Related]
14. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797 [TBL] [Abstract][Full Text] [Related]
15. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951 [TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]. Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798 [TBL] [Abstract][Full Text] [Related]
17. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282 [TBL] [Abstract][Full Text] [Related]
18. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413 [TBL] [Abstract][Full Text] [Related]
19. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Masciullo V; Ferrandina G; Pucci B; Fanfani F; Lovergine S; Palazzo J; Zannoni G; Mancuso S; Scambia G; Giordano A Clin Cancer Res; 2000 Dec; 6(12):4816-22. PubMed ID: 11156240 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Hotakainen K; Bjartell A; Sankila A; Järvinen R; Paju A; Rintala E; Haglund C; Stenman UH Int J Oncol; 2006 Jan; 28(1):95-101. PubMed ID: 16327984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]